Here is how Context Therapeutics Inc. (CNTX) and Collegium Pharmaceutical (COLL) have performed compared to their sector so far this year.

Context Therapeutics Inc.'s acquisition of CT-95, targeting MSLN expressing solid tumors, brings another shot on goal for its pipeline of T cell engagers. CTIM-76 is another T cell engager in the pipe...

Hypergrowth stocks are the holy grail of traders and growth investors. These stocks can multiply a small position by two, five, 10 times, or more.

Biotech stocks are naturally an exciting area for investment. Just one therapeutic breakthrough can change the whole trajectory of the company.

Context Therapeutics Inc. (CNTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Context Therapeutics (NASDAQ:CNTX) has announced its third-quarter results, highlighting its progress in advancing its lead candidate, CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody, toward a ...

Context Therapeutics (NASDAQ:CNTX) Inc has announced what it called encouraging preclinical data regarding its preclinical asset, CTIM-76, a Claudin 6 (CLDN6) x CD3 T-cell engaging bispecific antibody...

Context Therapeutics (NASDAQ:CNTX) Inc. has announced its financial results for the second quarter ended June 30, 2023, highlighting that it has sufficient cash and cash equivalents to continue fundin...

Nasdaq ETF marked first six-week rally since Jan 2020. These stocks gained more than 100% during this time frame.

Context Therapeutics said its decision made during the first quarter to focus on developing its preclinical asset CTIM-76 has extended the company's cash runway into late 2024. CTIM-76, a Claudin 6 (C...

Context Therapeutics (NASDAQ:CNTX) Inc announced that an abstract regarding its preclinical candidate, CTIM-76, a Claudin 6 x CD3 bispecific antibody, has been selected for poster presentation at the ...

Context Therapeutics (NASDAQ:CNTX) has announced a portfolio prioritization and capital allocation strategy that is expected to extend its cash runway into late 2024.  Releasing its full-year 2022 fin...

Context Therapeutics (NASDAQ:CNTX) Inc has highlighted encouraging clinical responses from its Phase 2 OATH clinical trial evaluating ONA-XR to treat endometrial cancer. The company said that two pati...

Penny Stocks With News Light Up The Scanners This Week This week

Context Therapeutics (NASDAQ:CNTX) has announced that its clinical trial collaborator, Stemline Therapeutics Inc, a wholly-owned subsidiary of The Menarini Group, has received approval from the US Foo...

Context Therapeutics (NASDAQ:CNTX) Inc said it will be collaborating with Lonza, a global development and manufacturing partner to the pharma, biotech, and nutrition industries, to manufacture Context...

Hot penny stocks to watch with news this week. The post 5 Hot Penny Stocks To Watch This Week With Big News appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Context Therapeutics (NASDAQ:CNTX) Inc has indicated in its corporate guidance for 2023 that with ample cash on hand, the company has the scope to advance its pipeline programs. As of September 30, 20...

Context Therapeutics (NASDAQ:CNTX) has announced preliminary Phase 2 data from the ongoing SMILE trial of onapristone extended-release (ONA-XR), the company's novel, first-in-class, potent, orally adm...

Context Therapeutics (NASDAQ:CNTX) Inc has designated CTIM-76, a T cell-engaging bispecific antibody, as its lead clinical development candidate to target Claudin 6 (CLDN6) positive cancers, the compa...